ADARx Prices Upsized $446.3M IPO, AbbVie Buys 4.9% Stake

ADARx Pharmaceuticals priced its upsized initial public offering at $17.00 per share on 24 September 2026, selling 26,250,000 shares of common stock for gross proceeds of approximately $446.3 million, the San Diego-based siRNA developer announced. The company granted underwriters a 30-day option on up to 3,937,500 additional shares at the same price. Including a concurrent private placement to AbbVie at $17.00 per share, expected aggregate gross proceeds reach roughly $535.2 million. Shares begin trading on the Nasdaq Global Select Market on 25 September 2026 under the ticker "ADRX."

Context — why this ADARx IPO matters now

The listing lands as a late-stage clinical biotechnology company with a partnered pipeline seeks public capital. ADARx describes itself as focused on complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic conditions, including obesity.

The AbbVie participation is the structural feature that separates this deal from a standard biotech float. The report states AbbVie agreed to buy shares in a concurrent private placement exempt from Securities Act registration, sized so AbbVie would own approximately 4.9% of ADARx's outstanding common stock after both closings, at $17.00 per share, capped at $100.0 million.

That cap explains the math. At $17.00, $100.0 million buys about 5.88 million shares, which is the ceiling on AbbVie's order. The equity stake floats with the final share count rather than being fixed at a flat dollar amount.

The report frames the private placement as contingent on the IPO closing, while the IPO is not contingent on the placement. That asymmetry means the public offering proceeds of about $446.3 million stand on their own, and the AbbVie subscription is incremental rather than load-bearing.

ADARx already has a relationship with AbbVie. The company said it has entered a collaboration and license option agreement with AbbVie covering siRNA therapeutics across neuroscience, immunology and oncology. The equity purchase extends an existing corporate tie into the shareholder register.

Data — the numbers behind the ADARx offering

Item	Figure
Public offering price	$17.00 per share
Shares offered by ADARx	26,250,000
Gross IPO proceeds	~$446.3 million
Underwriter option	3,937,500 shares, 30 days
AbbVie private placement cap	$100.0 million at $17.00
AbbVie pro forma stake	~4.9% of outstanding shares
Combined gross proceeds	~$535.2 million
Expected first trade	25 September 2026, "ADRX"
Expected close	28 September 2026

All shares in the public offering are being sold by ADARx, so no existing holders are liquidating into the float, based on the report. The combined figure of about $535.2 million excludes any exercise of the underwriters' option.

The book is led by J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank as lead book-running managers, with LifeSci Capital as a book-running manager. Registration statements became effective on 24 September 2026.

ADARx did not disclose a valuation, a market capitalization, a share count outstanding before the offering, or a use-of-proceeds breakdown. Those details sit in the prospectus rather than the pricing release.

Analysis — what the ADRX listing means for biotech

The deal's significance for sector watchers lies in the AbbVie cap. A $100.0 million ceiling paired with a 4.9% target stake implies AbbVie sized its order around ownership percentage, not a fixed check. If the offering had been smaller, the dollar figure would have been lower; the 4.9% is the binding constraint at the top end.

That structure gives ADARx a strategic holder with an existing licensing relationship, which can matter for pipeline validation. It also means roughly one-fifth of the combined proceeds arrive through a private channel rather than the public book, a split that affects how the float trades on day one.

Second-order read-through touches the broader siRNA and RNA-interference space, where ADARx competes for clinical and capital attention. A completed upsized listing at a single clearing price provides a fresh reference point for private peers weighing their own windows.

The clear counter-argument is that a $446.3 million raise does not by itself signal broad IPO demand. It reflects one company's pipeline stage and one strategic buyer's appetite. Single-deal enthusiasm can overstate the health of the wider listing market, and clinical-stage biotech remains exposed to trial outcomes that no financing removes.

Positioning is split. Public-book investors receive standard registered shares, while AbbVie holds privately placed stock at the same $17.00 price with no discount disclosed in the report. The absence of a stated discount is unusual relative to typical strategic placements and is worth flagging as a term the company did not detail.

Outlook — what to watch after the ADRX pricing

The first checkpoint is 25 September 2026, when "ADRX" is expected to begin trading on the Nasdaq Global Select Market. The opening print against the $17.00 offer price is the immediate signal on demand.

The second is 28 September 2026, the expected closing date for both the IPO and the concurrent private placement, subject to customary conditions. Any delay in the AbbVie placement would leave the public offering intact under the stated contingency structure.

The third is the underwriters' 30-day option on 3,937,500 shares. Exercise would add to gross proceeds and change the final share count, which in turn shifts where AbbVie's 4.9% lands.

There are no price levels to watch beyond the $17.00 offer, since the stock has not yet traded. Investors should track the prospectus for share count and use of proceeds once filed.

Frequently Asked Questions

What does the AbbVie investment in ADARx mean for retail investors?

AbbVie is buying privately placed shares at $17.00, the same price as the public offering, capped at $100.0 million and sized to about 4.9% ownership. For retail buyers in the float, it signals a strategic holder with an existing licensing agreement is committing capital alongside them, though the placement is contingent on the IPO closing and AbbVie's stake carries no disclosed governance rights.

When will ADRX stock start trading and on which exchange?

ADARx said its common stock is expected to begin trading on The Nasdaq Global Select Market on 25 September 2026 under the ticker symbol "ADRX." The offering itself is expected to close on 28 September 2026, subject to customary closing conditions. Until the first trade, there is no public market price to reference beyond the $17.00 offer price.

How much did ADARx raise and how is the deal split?

The public offering covers 26,250,000 shares at $17.00 for about $446.3 million in gross proceeds. The concurrent AbbVie private placement adds up to $100.0 million at the same price, bringing combined expected gross proceeds to roughly $535.2 million before discounts, commissions, placement agent fees and expenses, and excluding any underwriter option exercise.

Bottom Line

ADARx raised $446.3 million at $17.00 a share, with AbbVie's capped $100.0 million placement anchoring the combined $535.2 million deal.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.